Zeidler C
Abteilung für Molekulare Hämatopoese, Kinderklinik, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Z Rheumatol. 2013 Sep;72(7):663-8. doi: 10.1007/s00393-013-1163-4.
Severe chronic neutropenia (SCN) comprises a heterogeneous group of disorders with a common hematological and clinical phenotype characterized by absolute neutrophil counts (ANC) below 0,5 • 10(9)/l and increased risk of severe bacterial infections. The differentiation between primary and secondary neutropenia and the identification of causative gene mutations is of great importance for the estimation of prognosis. During childhood primary autoimmune neutropenia is the most frequent diagnosis, while secondary neutropenia predominates in adulthood. Despite the rarity, congenital, genetic neutropenias are of great value for research on normal and pathological hematopoiesis and have a fundamental impact on the current knowledge on hematopoiesis. To date mutations in more than 10 genes have been described which are mainly associated with an increased risk for leukemia.The treatment with hematopoietic growth factors has improved the long-term prognosis of SCN patients dramatically: Bacterial infections can be prevented and a normal participation in everyday life is possible.
严重慢性中性粒细胞减少症(SCN)是一组异质性疾病,具有共同的血液学和临床表型,其特征为绝对中性粒细胞计数(ANC)低于0.5×10⁹/L,且严重细菌感染风险增加。区分原发性和继发性中性粒细胞减少症以及确定致病基因突变对于预后评估至关重要。儿童期原发性自身免疫性中性粒细胞减少症是最常见的诊断,而继发性中性粒细胞减少症在成年期占主导。尽管罕见,但先天性、遗传性中性粒细胞减少症对于正常和病理性造血研究具有重要价值,并且对当前的造血知识有根本性影响。迄今为止,已描述了10多个基因的突变,这些突变主要与白血病风险增加有关。造血生长因子治疗显著改善了SCN患者的长期预后:可以预防细菌感染,患者能够正常参与日常生活。